XOMA Corp (XOMA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
XOMA Corp stock (XOMA) is currently trading at $29.22. XOMA Corp PE ratio is 38.28. XOMA Corp PS ratio (Price-to-Sales) is 6.82. Analyst consensus price target for XOMA is $65.75. WallStSmart rates XOMA as Hold.
- XOMA PE ratio analysis and historical PE chart
- XOMA PS ratio (Price-to-Sales) history and trend
- XOMA intrinsic value — DCF, Graham Number, EPV models
- XOMA stock price prediction 2025 2026 2027 2028 2029 2030
- XOMA fair value vs current price
- XOMA insider transactions and insider buying
- Is XOMA undervalued or overvalued?
- XOMA Corp financial analysis — revenue, earnings, cash flow
- XOMA Piotroski F-Score and Altman Z-Score
- XOMA analyst price target and Smart Rating
XOMA Corp
📊 No data available
Try selecting a different time range
XOMA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · XOMA Corp (XOMA)
XOMA trades 356% above its Graham fair value of $5.10, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
XOMA Corp (XOMA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, revenue growth, profit margin. Concerns around peg ratio and eps growth. Fundamentals are solid but monitor weak areas for improvement.
XOMA Corp (XOMA) Key Strengths (4)
Every $100 of shareholder equity generates $34 in profit
Revenue surging 57.90% year-over-year
Keeps $61 of every $100 in revenue as net profit
73.41% of shares held by major funds and institutions
Supporting Valuation Data
XOMA Corp (XOMA) Areas to Watch (6)
PEG ratio is negative or unavailable
Earnings declining -47.80%, profits shrinking
Premium valuation at 6.8x annual revenue
Premium pricing at 3.2x book value
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Supporting Valuation Data
XOMA Corp (XOMA) Detailed Analysis Report
Overall Assessment
This company scores 57/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Profit Margin. Profitability is solid with Return on Equity at 34.10%, Profit Margin at 60.80%. Growth metrics are encouraging with Revenue Growth at 57.90%.
The Bear Case
The primary concerns are PEG Ratio, EPS Growth, Price/Sales. Some valuation metrics including PEG Ratio (N/A), Price/Sales (6.82), Price/Book (3.16) suggest expensive pricing. Growth concerns include EPS Growth at -47.80%, which may limit upside. Profitability pressure is visible in Operating Margin at 15.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 34.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 57.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Revenue Growth) and negatives (PEG Ratio, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XOMA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XOMA's Price-to-Sales ratio of 6.82x trades 81% above its historical average of 3.76x (88th percentile), historically expensive. The current valuation is 91% below its historical high of 79.23x set in Dec 2017, and 16950% above its historical low of 0.04x in Jul 2010.
WallStSmart Analysis Synopsis
Data-driven financial summary for XOMA Corp (XOMA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
XOMA Corp is a strong growth company balancing expansion with improving profitability. Revenue reached 52M with 58% growth year-over-year. Profit margins are strong at 60.8%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 58% YoY, reaching 52M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 34.1% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Earnings fell 48% YoY while revenue grew 58%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can XOMA Corp maintain 58%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact XOMA Corp.
Bottom Line
XOMA Corp offers an attractive blend of growth (58% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About XOMA Corp(XOMA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.